By 2030, a diabetes prevention and treatment system will enable over 60% of residents aged 18 and above to be aware of the disease. By then, the coverage rate of standardized management services for type 2 diabetes patients at the primary level will exceed 70%, according to the documents released by multiple departments including the National Health Commission (NHC).

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy.

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

The World Health Organization on Thursday announced that it has published a fourth edition of its essential diagnostics list (EDL) adding tests for the hepatitis E virus and recommendations related to access to personal-use glucose monitoring devices.

Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.

The penetration rate of blood glucose meters among diabetes patients in China is far lower than that in developed countries, and there is a huge market space for blood glucose meters.

On April 6, Sinocare released its annual report for 2022.

Astellas Pharma and Roche Diabetes Care Japan have signed an agreement to develop and commercialise the latter’s Accu-Chek Guide Me blood glucose monitoring system as a combined medical product with BlueStar.

POCT is a clinical test that is performed next to the patient and sampled on-site for immediate analysis. Simplicity and convenience are always the most important features of POCT.

MilliporeSigma and 10x Genomics announced on Wednesday a collaboration on single-cell CRISPR screening workflows. The workflows will combine MilliporeSigmas CRISPR genome editing reagents with 10xs Feature Barcode assay to enable single-cel